<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Anesthesia for dialysis patients
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Anesthesia for dialysis patients
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Anesthesia for dialysis patients
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeremy P Campbell, MB, ChB (Hons.), MRCS, FRCA
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jonathan M Cousins, BSc, MBBS, FRCA, FFICM
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Stephanie B Jones, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeffrey S Berns, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael F O'Connor, MD, FCCM
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nancy A Nussmeier, MD, FAHA
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Eric N Taylor, MD, MSc, FASN
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 16, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H3969994670">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         End-stage kidney disease (ESKD) requiring dialysis is a growing problem worldwide (see
         <a class="medical medical_review" href="/z/d/html/7236.html" rel="external">
          "Epidemiology of chronic kidney disease"
         </a>
         ). Patients on dialysis commonly require surgery and invasive procedures for reasons related to ESKD, including vascular access, parathyroidectomy, and kidney transplantation. Patients may also require elective or emergency surgical procedures for reasons unrelated to their ESKD.
        </p>
        <p>
         This topic reviews anesthetic management of patients on dialysis. Preoperative and postoperative medical management of these patients is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1899.html" rel="external">
          "Medical management of the dialysis patient undergoing surgery"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2439405447">
         <span class="h1">
          PREANESTHETIC MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H457460629">
         <span class="h2">
          Elective surgery: Assessment and medication management
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Assessment of comorbidities
         </strong>
         – Patients with end-stage kidney disease (ESKD) on dialysis are assessed for comorbidities that may impact anesthetic and surgical care, including cardiovascular disease, hypertension, diabetes, anemia, bleeding diathesis, and nutritional status. These are discussed in a separate topic. (See
         <a class="medical medical_review" href="/z/d/html/1899.html" rel="external">
          "Medical management of the dialysis patient undergoing surgery", section on 'Assessment of comorbidities'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dialysis considerations
         </strong>
         – The type and location of dialysis access are noted. Preoperative hemodialysis or peritoneal dialysis considerations for patients with ESKD are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1899.html" rel="external">
          "Medical management of the dialysis patient undergoing surgery", section on 'Routine dialysis prior to surgery'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1867.html" rel="external">
          "Risk factors and prevention of peritonitis in peritoneal dialysis", section on 'All procedures'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preoperative medication management
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Chronically administered medications
         </strong>
         – Management of chronically administered medications for patients on dialysis is similar to that for patients without ESKD, as discussed in other topics. (See
         <a class="medical medical_review" href="/z/d/html/1899.html" rel="external">
          "Medical management of the dialysis patient undergoing surgery", section on 'Medication management'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4814.html" rel="external">
          "Perioperative medication management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Premedication
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Aspiration prophylaxis
         </strong>
         – Gastroparesis associated with diabetes may increase the risk of pulmonary aspiration during induction of general anesthesia [
         <a href="#rid1">
          1,2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1897.html" rel="external">
          "Unique aspects of gastrointestinal disease in patients on dialysis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Anxiolytics
         </strong>
         – Use of intravenous (IV)
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         to treat anxiety in the immediate preoperative period is avoided or administered in reduced titrated doses (typically 0.5 mg increments). Protein binding of midazolam is decreased in ESKD, resulting in increased plasma levels of free midazolam [
         <a href="#rid3">
          3,4
         </a>
         ]. Furthermore, elimination of midazolam and its main metabolite, a1-hydroxymidazolam, is reduced in patients with ESKD [
         <a href="#rid5">
          5,6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/94533.html" rel="external">
          "General anesthesia: Intravenous induction agents", section on 'Midazolam'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Opioids
         </strong>
         – If an IV opioid is necessary to treat pain in the immediate preoperative period, doses are reduced and titrated (eg,
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         administered in 25 mcg increments). (See
         <a class="medical medical_review" href="/z/d/html/94536.html" rel="external">
          "Perioperative uses of intravenous opioids in adults: General considerations", section on 'Preinduction'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2014874536">
         <span class="h2">
          Emergency surgery considerations
         </span>
         <span class="headingEndMark">
          —
         </span>
         For emergency surgical procedures, the nephrology service should be consulted when urgent preoperative dialysis (if feasible) may be desirable to treat severe hyperkalemia, metabolic acidosis, or intravascular volume overload. Institution of alternative therapies may be necessary if dialysis is not feasible. (See
         <a class="medical medical_review" href="/z/d/html/1899.html" rel="external">
          "Medical management of the dialysis patient undergoing surgery", section on 'Indications for urgent preoperative dialysis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3866695042">
         <span class="h3">
          Management of hyperkalemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hyperkalemia is a potential indication for consultation with the nephrologist to assess the need for preoperative dialysis, although there are no guidelines that specify a maximum safe level of potassium prior to induction of anesthesia. Furthermore, there is neither an orderly progression of electrocardiographic (ECG) abnormalities in individual patients as potassium rises, nor does the absence of ECG changes preclude the possibility of hyperkalemia-associated cardiac arrest [
         <a href="#rid7">
          7-10
         </a>
         ]. However, we avoid
         <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">
          succinylcholine
         </a>
         (SCh) if the potassium level is ≥5.5 mEq/L or if any ECG changes are evident. (See
         <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">
          "Clinical use of neuromuscular blocking agents in anesthesia", section on 'Succinylcholine'
         </a>
         .)
        </p>
        <p>
         Management of hyperkalemia for surgical emergencies depends on the individual's chronic and current potassium levels, and urgency of the procedure (ie, whether it is safe to delay surgery to perform dialysis). Other factors include the likely degree of tissue damage that may occur during the procedure to cause release of potassium, anticipated blood loss and fluid shifts, and whether the patient has acid-base disturbances (eg, metabolic acidosis) that may affect the intraoperative rate of rise of serum potassium concentration. For patients with potassium ≥5.5 mEq/L before or during emergency surgery:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We generally proceed with surgery with particular attention to continuous intraoperative ECG monitoring and intraoperative point-of-care measurements of potassium [
         <a href="#rid7">
          7,11
         </a>
         ]. We avoid use of SCh due to the potential for increasing the potassium level further and inducing life-threatening arrhythmias preceded by rapidly changing ECG findings [
         <a href="#rid10">
          10
         </a>
         ]. (See
         <a class="local">
          'Induction'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Ideally, discussions among the surgeon, anesthesiologist, and nephrologist weigh risks of proceeding against risks of delaying surgery for dialysis, particularly if any ECG features of hyperkalemia are present  (
         <a class="graphic graphic_figure graphicRef109443" href="/z/d/graphic/109443.html" rel="external">
          figure 1
         </a>
         ). Even one to two hours of hemodialysis typically reduces total body and serum potassium concentrations to a safer level.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a life-threatening surgical situation when dialysis is not feasible (eg, significant hemorrhage), the operation is performed regardless of potassium level and ECG changes. If potassium is &gt;6.5 mEq/L, the anesthesiologist must temporize with medical management of hyperkalemia. Specific treatments for such a hyperkalemic emergency include  (
         <a class="graphic graphic_algorithm graphicRef109740" href="/z/d/graphic/109740.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_table graphicRef74169" href="/z/d/graphic/74169.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid10">
          10
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/2332.html" rel="external">
          "Treatment and prevention of hyperkalemia in adults"
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         IV calcium (eg,
         <a class="drug drug_general" data-topicid="9186" href="/z/d/drug information/9186.html" rel="external">
          calcium chloride
         </a>
         500 to 1000 mg) to directly antagonize the cell membrane actions of hyperkalemia. Since hypocalcemia exacerbates potassium-induced cardiotoxicity, ionized calcium levels are monitored to avoid hypocalcemia. (See
         <a class="medical medical_review" href="/z/d/html/2332.html" rel="external">
          "Treatment and prevention of hyperkalemia in adults", section on 'Calcium'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         IV insulin (typically given with IV glucose) to drive extracellular potassium into cells. (See
         <a class="medical medical_review" href="/z/d/html/2332.html" rel="external">
          "Treatment and prevention of hyperkalemia in adults", section on 'Insulin with glucose'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If severe acute metabolic acidosis is present (ie, pH &lt;7.1 to 7.2), bicarbonate therapy 1 to 2 mEq/kg may be administered to raise pH and drive extracellular potassium into cells. The bicarbonate dose may be repeated if pH remains &lt;7.1 after 30 minutes. Details regarding management of this circumstance are discussed in other topics:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2353.html" rel="external">
          "Potassium balance in acid-base disorders", section on 'Metabolic acidosis'
         </a>
         .)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2291.html" rel="external">
          "Approach to the adult with metabolic acidosis", section on 'Overview of therapy'
         </a>
         .)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2294.html" rel="external">
          "Bicarbonate therapy in lactic acidosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Though rarely necessary, continuous kidney replacement therapy or hemodialysis can be performed in the operating room if equipment and personnel are available (eg, during cardiopulmonary bypass in a cardiac surgical procedure) [
         <a href="#rid12">
          12,13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H178239800">
         <span class="h3">
          Management of intravascular volume overload
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with hypervolemia, if time allows, discussions among the surgeon, anesthesiologist, and nephrologist weigh risks of moderate or severe preoperative volume overload against risks of delaying surgery for dialysis. Intravascular volume overload and pulmonary edema in the preoperative period may be exacerbated by infusion of fluid or transfusion during surgery, which may necessitate urgent postoperative dialysis and/or a period of noninvasive positive pressure ventilation or controlled mechanical ventilation. Patients who are on dialysis but nevertheless have some degree of residual kidney function and urine output may respond to high doses of loop diuretics.
        </p>
        <p class="headingAnchor" id="H639776749">
         <span class="h3">
          Management of bleeding
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with ESKD may have an increased tendency to bleed during and/or after surgery. (See
         <a class="medical medical_review" href="/z/d/html/1899.html" rel="external">
          "Medical management of the dialysis patient undergoing surgery", section on 'Uremic bleeding'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a patient with likely uremia-induced platelet dysfunction, we administer IV
         <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">
          desmopressin
         </a>
         (dDAVP) 0.3 mcg/kg. (See
         <a class="medical medical_review" href="/z/d/html/1947.html" rel="external">
          "Uremic platelet dysfunction", section on 'Acute life-threatening bleeding'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If a uremic patient is actively bleeding, we also administer platelets (one apheresis unit or six units of pooled platelets) even in the absence of thrombocytopenia. Notably, platelet therapy will only be transiently effective for uremic platelet dysfunction because transfused platelets are rendered dysfunctional by the uremic milieu with variable rapidity. (See
         <a class="medical medical_review" href="/z/d/html/7918.html" rel="external">
          "Platelet transfusion: Indications, ordering, and associated risks", section on 'Platelet function disorders'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Furthermore, during the intraoperative period, point-of-care tests of coagulation (eg, thromboelastography, rotational thromboelastometry) are obtained if available, as well as standard laboratory coagulation tests including prothrombin time, activated partial thromboplastin time, international normalized ratio, and platelet count. We also obtain tests of platelet function if available (eg, platelet aggregometry, PFA-100), although these may not be reliable for diagnosing uremic platelet dysfunction. (See
         <a class="medical medical_review" href="/z/d/html/4433.html" rel="external">
          "Platelet function testing"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/112610.html" rel="external">
          "Intraoperative transfusion and administration of clotting factors", section on 'Point-of-care tests'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/112610.html" rel="external">
          "Intraoperative transfusion and administration of clotting factors", section on 'Standard tests'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H126994394">
         <span class="h1">
          VASCULAR ACCESS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Obtaining intravascular access may be challenging in a patient on dialysis. Those receiving chronic hemodialysis typically have an arteriovenous fistula or graft or a hemodialysis catheter; access at these sites is avoided.
        </p>
        <p class="headingAnchor" id="H848291794">
         <span class="h2">
          Intravenous access
         </span>
        </p>
        <p class="headingAnchor" id="H1253546534">
         <span class="h3">
          General considerations
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Peripheral venous catheters
         </strong>
         – Ideally, the veins on the back of either hand are used. If these veins are inadequate and peripheral venous access is necessary more proximally in an upper limb, the dominant arm is preferred because the nondominant arm is typically used for arteriovenous access.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If the patient already has arteriovenous access in the upper limb, the other arm should be used for peripheral venous catheters. As a last resort, the veins distal to arteriovenous access may be used, provided there is no plan to use those veins for future arteriovenous access.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Peripherally inserted central catheters (PICC) should be avoided in patients on dialysis in order to preserve the superficial veins for future arteriovenous fistulae. If a PICC line is necessary, a tunneled PICC line is preferred.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Central venous catheters
         </strong>
         – Central venous catheter (CVC) placement may be difficult, particularly if hemodialysis catheters have previously been inserted into central veins. Any previous studies of the patient's vascular anatomy should be reviewed for relevant information (eg, occluded internal jugular, subclavian, or femoral veins or the presence of vascular stents).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A new CVC should not be placed on the same side as an existing hemodialysis catheter. Also, placement of a CVC in a subclavian vein is avoided because of the possibility of inducing subclavian stenosis that may preclude subsequent creation of an arteriovenous fistula in the ipsilateral arm. (See
         <a class="medical medical_review" href="/z/d/html/17036.html" rel="external">
          "Overview of thoracic central venous obstruction", section on 'Intravascular device related'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1913.html" rel="external">
          "Central vein obstruction associated with upper extremity hemodialysis access", section on 'Central venous catheters'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We use ultrasound guidance during insertion of a CVC, particularly in the internal jugular vein location and in sites where the patient has a history of prior vascular instrumentation or venous thrombosis. Compared with the anatomic landmark approach, ultrasound guidance has been shown to result in a higher overall successful cannulation rate and a decreased rate of arterial puncture or pneumothorax [
         <a href="#rid14">
          14-16
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6315.html" rel="external">
          "Basic principles of ultrasound-guided venous access"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8194.html" rel="external">
          "Central venous access in adults: General principles"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2567059657">
         <span class="h3">
          Avoid dialysis access
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Arteriovenous fistula or graft
         </strong>
         – Venipuncture and vascular access at current fistula or graft sites must be avoided. Exceptions occur in emergency situations or when alternative vascular access is impossible. If using an arteriovenous fistula or graft is essential, cannulation should ideally be performed by an experienced dialysis nurse or technician. (See
         <a class="medical medical_review" href="/z/d/html/1899.html" rel="external">
          "Medical management of the dialysis patient undergoing surgery", section on 'Intravenous access'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         During surgery, meticulous care of an existing fistula is essential to avoid potential thrombosis. This includes avoiding blood pressure measurements or needle sticks in the extremity with the fistula. Also, direct pressure on the fistula should be avoided during patient positioning and throughout the perioperative period.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Potential future fistula sites should also be avoided because of the risk of damaging these blood vessels (eg, veins in the antecubital fossa and the cephalic vein at the wrist, especially in the nondominant arm).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemodialysis catheter
         </strong>
         – Generally, a hemodialysis catheter should not be used for purposes other than dialysis. Exceptions may occur in an emergency situation when alternative vascular access is challenging, or to avoid multiple attempts to obtain IV access or insertion of a new CVC [
         <a href="#rid17">
          17
         </a>
         ]. If use is necessary, residual heparin in the catheter must be aspirated and discarded before use, and the catheter must be appropriately flushed and reheparinized after use.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3533893445">
         <span class="h2">
          Intra-arterial access and blood pressure monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         If intra-arterial blood pressure monitoring is planned, results of previously performed Doppler vascular studies or point-of-care ultrasound may be helpful for selection of potential sites for arterial catheter insertion. (See
         <a class="medical medical_review" href="/z/d/html/8174.html" rel="external">
          "Intra-arterial catheterization for invasive monitoring: Indications, insertion techniques, and interpretation", section on 'Use of ultrasound guidance'
         </a>
         .)
        </p>
        <p>
         The extremity with a currently functioning fistula or graft site is avoided.
        </p>
        <p class="headingAnchor" id="H160204447">
         <span class="h1">
          INTRAOPERATIVE ANESTHETIC MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H519758830">
         <span class="h2">
          Local anesthesia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Local anesthesia with monitored anesthesia care (MAC) is often selected for patients on dialysis if this choice is appropriate for the surgical procedure. (See
         <a class="medical medical_review" href="/z/d/html/94529.html" rel="external">
          "Monitored anesthesia care in adults", section on 'Appropriateness of monitored anesthesia care'
         </a>
         .)
        </p>
        <p>
         Advantages for patients with end-stage kidney disease (ESKD) include avoiding a potentially hazardous general anesthetic in a patient with significant comorbidities, and avoiding the need to administer multiple intravenous (IV) anesthetic agents that may have delayed metabolism and excretion.
        </p>
        <p>
         During MAC, small titrated doses of IV sedative, anxiolytic, or analgesic agents may be administered as necessary  (
         <a class="graphic graphic_table graphicRef110394" href="/z/d/graphic/110394.html" rel="external">
          table 2
         </a>
         ). Agents with rapid onset and short duration of action are preferred to allow rapid titration of effects and quick recovery. Notably, these agents can cause respiratory depression and hypotension in a dose-dependent manner. Furthermore, metabolism may be delayed in patients with ESKD due to variability in volume of distribution, degree of plasma protein binding, and excretion. We preferentially employ
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         infusion in these patients, and we minimize use of opioids and avoid benzodiazepines. (See
         <a class="medical medical_review" href="/z/d/html/94529.html" rel="external">
          "Monitored anesthesia care in adults", section on 'Drugs used for sedation and analgesia for monitored anesthesia care'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1094973178">
         <span class="h2">
          Regional anesthesia
         </span>
         <span class="headingEndMark">
          —
         </span>
         A regional anesthetic technique such as a peripheral nerve block or a neuraxial (spinal or epidural) anesthetic is often selected for patients on dialysis if this choice is appropriate for the surgical procedure. Considerations unique to patients with ESKD include the possibility of slow onset of action of the selected local anesthetic agent due to low serum bicarbonate level and possible shortened duration of local anesthetic action due to reduced protein binding [
         <a href="#rid17">
          17
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/397.html" rel="external">
          "Overview of peripheral nerve blocks", section on 'Use of nerve blocks'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/89517.html" rel="external">
          "Overview of neuraxial anesthesia", section on 'Use of neuraxial anesthesia'
         </a>
         .)
        </p>
        <p>
         Similar to local anesthetic techniques with MAC, an advantage of a regional technique is avoidance of a potentially hazardous general anesthetic and the need to administer multiple IV anesthetic agents. If necessary, supplemental IV sedative, anxiolytic, or analgesic agents may be administered in small titrated doses; however, benzodiazepines are avoided and opioids are minimized. (See
         <a class="local">
          'Local anesthesia'
         </a>
         above.)
        </p>
        <p>
         Another advantage is the superior postoperative analgesia that neuraxial or peripheral blocks typically provide, with reduced requirements for systemic analgesic agents (particularly opioids). Furthermore, these techniques may improve patency and lower failure rates for vascular surgical procedures to provide dialysis access [
         <a href="#rid18">
          18-20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/89517.html" rel="external">
          "Overview of neuraxial anesthesia", section on 'General versus neuraxial anesthesia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/130312.html" rel="external">
          "Approach to the management of acute pain in adults", section on 'Regional anesthesia techniques'
         </a>
         .).
        </p>
        <p>
         In selected patients with coagulopathy or significant bleeding diathesis or recent anticoagulation with heparin (eg, for hemodialysis), a disadvantage is the need to avoid regional techniques such as neuraxial anesthesia, paravertebral blocks, and deep plexus blocks (eg, lumbar plexus). A coagulation profile (eg, international normalized ratio, partial thromboplastin time, platelet count) is checked before beginning such regional techniques. Furthermore, if the patient has received heparin during postoperative dialysis, the coagulation profile should be checked prior to removal of a neuraxial catheter in the postoperative period [
         <a href="#rid21">
          21-23
         </a>
         ]. (See
         <a class="local">
          'Management of bleeding'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/14930.html" rel="external">
          "Neuraxial anesthesia/analgesia techniques in the patient receiving anticoagulant or antiplatelet medication"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1094973649">
         <span class="h2">
          General anesthesia
         </span>
         <span class="headingEndMark">
          —
         </span>
         General anesthesia is necessary for many surgical procedures (see
         <a class="medical medical_review" href="/z/d/html/399.html" rel="external">
          "Overview of anesthesia", section on 'Selection of anesthetic technique'
         </a>
         ). Metabolism and elimination of many IV anesthetic agents may be delayed in patients with ESKD due to impairment of glomerular filtration and renal tubular function, leading to accumulation of the drugs and their metabolites. Also, the volume of distribution and degree of plasma protein binding of anesthetic drugs may be altered, resulting in higher-than-expected plasma concentrations.
        </p>
        <p class="headingAnchor" id="H3801553334">
         <span class="h3">
          Induction
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sedative-hypnotic anesthetic induction and adjuvant agents
         </strong>
         – We typically induce general anesthesia with a reduced and carefully titrated dose of the sedative-hypnotic induction agent
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         (eg, 1 to 2 mg/kg) because the pharmacokinetic and pharmacodynamic responses to this agent are not markedly altered by ESKD [
         <a href="#rid24">
          24,25
         </a>
         ]. Administration of higher bolus doses of propofol may result in profound hypotension due to venous and arterial dilation, as well as decreased myocardial contractility. (See
         <a class="medical medical_review" href="/z/d/html/94533.html" rel="external">
          "General anesthesia: Intravenous induction agents", section on 'Propofol'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A different sedative-hypnotic agent may be selected based on patient- or procedure-specific factors  (
         <a class="graphic graphic_table graphicRef102350" href="/z/d/graphic/102350.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/94533.html" rel="external">
          "General anesthesia: Intravenous induction agents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Agents to facilitate endotracheal intubation
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          NMBAs for patients who require rapid sequence induction and intubation
         </strong>
         – Properties of neuromuscular blocking agents (NMBAs) are noted in the table  (
         <a class="graphic graphic_table graphicRef114271" href="/z/d/graphic/114271.html" rel="external">
          table 4
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">
          Succinylcholine
         </a>
         <strong>
          for patients with potassium concentration &lt;5.5 mEq/L
         </strong>
         – Succinylcholine (SCh) is typically selected to facilitate laryngoscopy for patients requiring rapid sequence induction and intubation (RSII) due to risk of aspiration (see
         <a class="medical medical_review" href="/z/d/html/94214.html" rel="external">
          "Rapid sequence induction and intubation (RSII) for anesthesia", section on 'Succinylcholine'
         </a>
         ). If the potassium concentration is &lt;5.5 mEq/L and there are no electrocardiographic (ECG) changes, SCh can be safely used in patients on dialysis [
         <a href="#rid26">
          26
         </a>
         ]. As in healthy patients, a transient potassium increase of approximately 0.5 to 1 mEq/L is observed after SCh administration, but this hyperkalemic response is not exaggerated in patients with ESKD. Notably, patients with ESKD have reduced levels of plasma cholinesterase, the enzyme that metabolizes SCh. Hence, the neuromuscular block caused by SCh may be prolonged [
         <a href="#rid27">
          27
         </a>
         ]. However, we avoid SCh if the potassium level is ≥5.5 mEq/L or if any ECG changes are evident. (See
         <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">
          "Clinical use of neuromuscular blocking agents in anesthesia", section on 'Succinylcholine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="9872" href="/z/d/drug information/9872.html" rel="external">
          Rocuronium
         </a>
         <strong>
          for patients with potassium concentration ≥5.5 mEq/L
         </strong>
         – For patients with a potassium level ≥5.5 mEq/L who require RSII, we use a relatively large dose of rocuronium (1 mg/kg) if RSII is necessary. Although rocuronium is primarily eliminated by direct liver uptake and excretion in bile, some is excreted by the kidneys. Thus, neuromuscular blockade may be markedly prolonged after administration of a large dose suitable for RSII (see
         <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">
          "Clinical use of neuromuscular blocking agents in anesthesia", section on 'Sugammadex'
         </a>
         ). Although neuromuscular blockade due to rocuronium can be reversed with
         <a class="drug drug_general" data-topicid="105866" href="/z/d/drug information/105866.html" rel="external">
          sugammadex
         </a>
         , removal of the sugammadex/rocuronium complex by dialysis may be necessary due to concerns about the possibility of dissociation of the complex with recurrence of paralysis. (See
         <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">
          "Clinical use of neuromuscular blocking agents in anesthesia", section on 'Sugammadex'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          NMBAs for patients who do not require rapid sequence induction and intubation
         </strong>
         – Either the nondepolarizing NMBA
         <a class="drug drug_general" data-topicid="8973" href="/z/d/drug information/8973.html" rel="external">
          atracurium
         </a>
         ,
         <a class="drug drug_general" data-topicid="9270" href="/z/d/drug information/9270.html" rel="external">
          cisatracurium
         </a>
         , or
         <a class="drug drug_general" data-topicid="9872" href="/z/d/drug information/9872.html" rel="external">
          rocuronium
         </a>
         is typically selected to facilitate laryngoscopy if RSII is not necessary. Elimination of atracurium or cisatracurium is independent of kidney function [
         <a href="#rid28">
          28-30
         </a>
         ]. However, because of slow onset (three to four minutes for atracurium and five to seven minutes for cisatracurium), these agents are not ideal for RSII. As noted above, rocuronium is a suitable alternative, particularly for patients requiring RSII. (See
         <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">
          "Clinical use of neuromuscular blocking agents in anesthesia", section on 'Atracurium'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">
          "Clinical use of neuromuscular blocking agents in anesthesia", section on 'Cisatracurium'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">
          "Clinical use of neuromuscular blocking agents in anesthesia", section on 'Rocuronium'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">
          Remifentanil
         </a>
         <strong>
          intubation technique
         </strong>
         – A remifentanil intubation technique can be used to facilitate laryngoscopy for patients who do not require RSII, thereby avoiding use of a NMBA. For this technique,
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         1 to 2 mg/kg is administered followed by a relatively high dose of the ultrashort-acting opioid remifentanil (eg, 2 to 3 mcg/kg). This results in good intubating conditions in approximately two minutes. We administer
         <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">
          ephedrine
         </a>
         10 mg together with the doses of propofol and remifentanil to minimize the profound bradycardia and hypotension that may otherwise result from combining large doses of both agents, particularly in a patient with ESKD. (See
         <a class="medical medical_review" href="/z/d/html/94214.html" rel="external">
          "Rapid sequence induction and intubation (RSII) for anesthesia", section on 'Remifentanil intubation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">
          Sevoflurane
         </a>
         <strong>
          during induction
         </strong>
         – Sevoflurane can be used
         <strong>
         </strong>
         instead of
         <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">
          remifentanil
         </a>
         , with administration of 3.5% for approximately three minutes, followed by administration of a reduced dose or
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         (0.5 to 1 mg/kg).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1094973917">
         <span class="h3">
          Maintenance
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inhalation or total intravenous anesthesia (TIVA) techniques
         </strong>
         – Either an inhalation-based technique or TIVA is a reasonable choice to maintain general anesthesia. Typically, a combination of inhalation and IV agents is employed. (See
         <a class="medical medical_review" href="/z/d/html/96308.html" rel="external">
          "Maintenance of general anesthesia: Overview"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Inhalation anesthetic technique
         </strong>
         – Any one of the potent volatile agents (eg,
         <a class="drug drug_general" data-topicid="8992" href="/z/d/drug information/8992.html" rel="external">
          isoflurane
         </a>
         ,
         <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">
          sevoflurane
         </a>
         ,
         <a class="drug drug_general" data-topicid="8891" href="/z/d/drug information/8891.html" rel="external">
          desflurane
         </a>
         ) may be administered with or without
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          nitrous oxide
         </a>
         (N
         <sub>
          2
         </sub>
         O). Sevoflurane has been used safely in patients with stable chronic kidney disease and those on dialysis [
         <a href="#rid31">
          31-41
         </a>
         ]. This is despite concerns that have been expressed regarding the theoretical kidney toxicity of sevoflurane due to its inorganic fluoride ion metabolite [
         <a href="#rid42">
          42
         </a>
         ] and formation of a substance known as "Compound A," particularly when low fresh gas flows are used or higher temperatures are present in the breathing circuit [
         <a href="#rid43">
          43-45
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/114826.html" rel="external">
          "Inhalation anesthetic agents: Clinical effects and uses", section on 'Sevoflurane'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          TIVA technique
         </strong>
         – We typically use a continuous IV infusion of both a hypnotic agent (usually
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         at 50 to 150 mcg/kg/minute) and a short-acting opioid (usually
         <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">
          remifentanil
         </a>
         at 0.015 to 1 mcg/kg/minute). (See
         <a class="medical medical_review" href="/z/d/html/96308.html" rel="external">
          "Maintenance of general anesthesia: Overview", section on 'Total intravenous anesthesia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Use of opioids during maintenance
         </strong>
         – Although opioids are routinely used as adjuvant agents during maintenance of general anesthesia, we carefully titrate any selected short-acting opioid according to individual patient needs in order to avoid postoperative respiratory depression. (See
         <a class="medical medical_review" href="/z/d/html/96308.html" rel="external">
          "Maintenance of general anesthesia: Overview", section on 'Analgesic component: Opioid agents'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94536.html" rel="external">
          "Perioperative uses of intravenous opioids in adults: General considerations", section on 'Maintenance'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Short-acting opioids
         </strong>
         – Generally, the pharmacokinetic and pharmacodynamic responses to short-acting opioids (eg,
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         ,
         <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">
          remifentanil
         </a>
         , and
         <a class="drug drug_general" data-topicid="9954" href="/z/d/drug information/9954.html" rel="external">
          sufentanil
         </a>
         ) are not affected by ESKD, although interindividual variability exists [
         <a href="#rid46">
          46-49
         </a>
         ]. Also, acute alkalinization induced by hemodialysis may increase the distribution of opioids across the blood-brain barrier into cerebrospinal fluid. Thus, it is particularly important to monitor for perioperative respiratory depression [
         <a href="#rid49">
          49
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/94536.html" rel="external">
          "Perioperative uses of intravenous opioids in adults: General considerations", section on 'Prevention and management of adverse opioid effects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          Fentanyl
         </a>
         – We employ fentanyl in the majority of cases. It is predominantly metabolized in the liver to norfentanyl, an inactive metabolite. It has a short redistribution phase and its free fraction is not different in patients with ESKD compared with patients without ESKD. (See
         <a class="medical medical_review" href="/z/d/html/130113.html" rel="external">
          "Perioperative uses of intravenous opioids: Specific agents", section on 'Fentanyl'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">
          Remifentanil
         </a>
         – We typically use remifentanil without dose adjustment as the analgesic component of a TIVA technique. Remifentanil is rapidly broken down by nonspecific plasma and tissue esterases; thus, accumulation does not occur regardless of duration of administration. Remifentanil has a predictable offset of action, with a context-sensitive half-time that is consistent in patients with or without ESKD [
         <a href="#rid50">
          50
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/130113.html" rel="external">
          "Perioperative uses of intravenous opioids: Specific agents", section on 'Remifentanil'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Use of NMBAs during maintenance
         </strong>
         – We monitor the degree of neuromuscular blockade if a nondepolarizing NMBA is administered to facilitate conduct of the surgical procedure since interindividual variability in pharmacokinetic and pharmacodynamic responses are likely due to preexisting acidosis or alterations in volume of distribution  (
         <a class="graphic graphic_table graphicRef114271" href="/z/d/graphic/114271.html" rel="external">
          table 4
         </a>
         ). We generally prefer
         <a class="drug drug_general" data-topicid="9270" href="/z/d/drug information/9270.html" rel="external">
          cisatracurium
         </a>
         since elimination is independent of kidney function [
         <a href="#rid28">
          28-30
         </a>
         ]. Longer-acting NMBAs are avoided in patients with ESKD. (See
         <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">
          "Clinical use of neuromuscular blocking agents in anesthesia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9270" href="/z/d/drug information/9270.html" rel="external">
          Cisatracurium
         </a>
         – Cisatracurium is the
         <em>
          cis
         </em>
         -isomer of
         <a class="drug drug_general" data-topicid="8973" href="/z/d/drug information/8973.html" rel="external">
          atracurium
         </a>
         and is four times more potent than atracurium. In contrast with atracurium, it does not cause histamine release. Cisatracurium is also primarily metabolized through Hofmann elimination and has no active metabolites. (See
         <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">
          "Clinical use of neuromuscular blocking agents in anesthesia", section on 'Cisatracurium'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8973" href="/z/d/drug information/8973.html" rel="external">
          Atracurium
         </a>
         – Atracurium is metabolized through nonspecific plasma esterase-mediated hydrolysis and a nonenzymatic, pH- and temperature-dependent degradation called Hofmann elimination. Metabolism is essentially independent of hepatic and kidney function, and atracurium has no active metabolites. (See
         <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">
          "Clinical use of neuromuscular blocking agents in anesthesia", section on 'Atracurium'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Mivacurium
         </strong>
         – Mivacurium may be used in patients with ESKD undergoing surgical procedures that are of moderate duration (one or more hours). Mivacurium is hydrolyzed by plasma cholinesterase, like SCh, and does not have active metabolites. Its usual duration of action is 15 to 20 minutes, but recovery may be slower in patients with ESKD due to reduced plasma cholinesterase activity [
         <a href="#rid51">
          51
         </a>
         ]. Reversal (antagonism) of mivacurium with either
         <a class="drug drug_general" data-topicid="9693" href="/z/d/drug information/9693.html" rel="external">
          neostigmine
         </a>
         or
         <a class="drug drug_general" data-topicid="9403" href="/z/d/drug information/9403.html" rel="external">
          edrophonium
         </a>
         is faster than spontaneous recovery [
         <a href="#rid52">
          52
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">
          "Clinical use of neuromuscular blocking agents in anesthesia", section on 'Mivacurium'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9872" href="/z/d/drug information/9872.html" rel="external">
          Rocuronium
         </a>
         – Rocuronium is increasingly used in patients with ESKD (eg, for patients who required RSII during induction of anesthesia) (see
         <a class="local">
          'Induction'
         </a>
         above). Rocuronium is excreted mostly through the biliary route, but some is excreted by the kidneys such that clearance is reduced by 33 to 39 percent in patients with ESKD. Furthermore, its metabolism results in 17-desacetyl-rocuronium, a compound that has 20 percent the activity of the parent compound. (See
         <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">
          "Clinical use of neuromuscular blocking agents in anesthesia", section on 'Rocuronium'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3204126225">
         <span class="h2">
          Emergence
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following agents may be used to reverse the effects of NMBAs (see
         <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">
          "Clinical use of neuromuscular blocking agents in anesthesia", section on 'Reversal of neuromuscular block'
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9693" href="/z/d/drug information/9693.html" rel="external">
          Neostigmine
         </a>
         – Pharmacokinetics of typical single-dose administration of the anticholinesterase agent neostigmine at the end of surgery do not differ from patients with normal kidney function [
         <a href="#rid53">
          53
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">
          "Clinical use of neuromuscular blocking agents in anesthesia", section on 'Anticholinesterases'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="105866" href="/z/d/drug information/105866.html" rel="external">
          Sugammadex
         </a>
         – Sugammadex is a chelating agent that encapsulates
         <a class="drug drug_general" data-topicid="9872" href="/z/d/drug information/9872.html" rel="external">
          rocuronium
         </a>
         or
         <a class="drug drug_general" data-topicid="10041" href="/z/d/drug information/10041.html" rel="external">
          vecuronium
         </a>
         in order to rapidly reverse neuromuscular blockade [
         <a href="#rid54">
          54
         </a>
         ]. If high-dose rocuronium is used and reversed with sugammadex in a patient with ESKD (see
         <a class="local">
          'Induction'
         </a>
         above), the sugammadex-rocuronium complexes are retained in the body longer than in healthy patients before eventually being excreted by the kidneys. However, the clinical significance of this delay is not clear [
         <a href="#rid55">
          55,56
         </a>
         ]. Also, the sugammadex-rocuronium complex can be removed by dialysis [
         <a href="#rid57">
          57
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">
          "Clinical use of neuromuscular blocking agents in anesthesia", section on 'Sugammadex'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3171748403">
         <span class="h2">
          Intraoperative concerns
         </span>
        </p>
        <p class="headingAnchor" id="H853391881">
         <span class="h3">
          Fluid management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of IV fluid administration may be challenging in a patient on dialysis. Hypervolemia may lead to pulmonary edema, while hypovolemia may cause hemodynamic instability [
         <a href="#rid17">
          17
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14942.html" rel="external">
          "Intraoperative fluid management", section on 'Causes and consequences of intravascular volume derangements'
         </a>
         .)
        </p>
        <p>
         We administer fluids in 500 mL infusion bags with a micro-dripper to avoid fluid overload, unless large fluid shifts and/or a large volume of blood loss is likely. Fluid choices include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Crystalloids
         </strong>
         – We typically select a balanced electrolyte solution unless the patient has hyperkalemia. In such cases, we select normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         . However, administration of large volumes of normal saline may result in hyperchloremic metabolic acidosis compared with administration of balanced electrolyte solutions [
         <a href="#rid58">
          58,59
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14942.html" rel="external">
          "Intraoperative fluid management", section on 'Crystalloid solutions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Notably, patients with ESKD are at risk for development of hyperkalemia when nil per os (NPO; nothing by mouth) and receiving IV fluids without glucose. However, glucose-containing solutions are avoided in patients with hyperglycemia or if hypokalemia is present. If a glucose-containing solutions is administered, blood glucose levels should be monitored. (See
         <a class="local">
          'Glucose control'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Colloids
         </strong>
         – In rare circumstances when urgent and significant volume expansion is necessary in a patient with ESKD when transfusion of packed red blood cells (RBCs) is not available or is not indicated, 5% albumin is administered in the United States. Other colloid solutions (eg, Gelofusine) may be available for such situations in other nations. (See
         <a class="medical medical_review" href="/z/d/html/14942.html" rel="external">
          "Intraoperative fluid management", section on 'Colloid solutions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Blood
         </strong>
         – Perioperative blood transfusion is avoided when possible. However, if hemoglobin is &lt;7 g/dL, particularly with ongoing surgical bleeding, transfusion of RBCs is often necessary. Potassium should be checked regularly during transfusion since hyperkalemia may develop in an anuric patient.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Further discussion of transfusion and alternatives to transfusion in patients with ESKD is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/1899.html" rel="external">
          "Medical management of the dialysis patient undergoing surgery", section on 'Anemia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1926.html" rel="external">
          "Treatment of anemia in patients on dialysis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H853392005">
         <span class="h3">
          Glucose control
         </span>
         <span class="headingEndMark">
          —
         </span>
         We maintain blood glucose &lt;180 mg/dL (&lt;10 mmol/L) throughout the perioperative period in both patients with and without diabetes. Either hyperglycemia or hypoglycemia may occur, particularly in patients on dialysis with type 1 diabetes. Even in those without diabetes, glucose intolerance is a feature of uremia. Hyperglycemia is a common consequence of the administration of high doses of steroids in patients with ESKD.
        </p>
        <p>
         If insulin is administered, the serum glucose level is checked one hour later, or every 30 to 60 minutes when a perioperative insulin infusion is used [
         <a href="#rid60">
          60
         </a>
         ]. It is particularly important to avoid hypoglycemic episodes. Although hyperglycemia is associated with an approximately two- to fourfold increased risk of a myocardial ischemic event in noncardiac surgery [
         <a href="#rid61">
          61,62
         </a>
         ], attempts to tightly control glucose may cause harm due to inadvertent hypoglycemia [
         <a href="#rid63">
          63
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1600.html" rel="external">
          "Glycemic control in critically ill adult and pediatric patients"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H126994565">
         <span class="h1">
          POSTOPERATIVE ANALGESIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with end-stage kidney disease (ESKD) can be admitted to a post-anesthesia care unit depending on other procedure-specific and patient-specific factors. Those with hemodynamic instability, bleeding, electrolyte abnormalities, or volume overload are admitted to an intensive care unit. We use a multimodal approach to postoperative pain in either setting. (See
         <a class="medical medical_review" href="/z/d/html/130312.html" rel="external">
          "Approach to the management of acute pain in adults", section on 'Use multimodal analgesia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1899.html" rel="external">
          "Medical management of the dialysis patient undergoing surgery", section on 'Pain management'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Regional and local anesthetic techniques
         </strong>
         – For many types of surgical procedures, regional and local analgesic techniques such as neuraxial analgesia, peripheral nerve blocks, or wound infiltration with local anesthetic agents are encouraged as part of a multimodal pain management strategy to reduce or eliminate opioid requirements [
         <a href="#rid64">
          64
         </a>
         ]. (See
         <a class="local">
          'Regional anesthesia'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/130312.html" rel="external">
          "Approach to the management of acute pain in adults", section on 'Regional anesthesia techniques'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pharmacologic agents
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Nonopioid analgesics
         </strong>
         – Nonopioid pharmacologic agents such as
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         and
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         are often employed. (See
         <a class="medical medical_review" href="/z/d/html/133187.html" rel="external">
          "Nonopioid pharmacotherapy for acute pain in adults", section on 'Acetaminophen'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/133187.html" rel="external">
          "Nonopioid pharmacotherapy for acute pain in adults", section on 'Ketamine'
         </a>
         .)
         <strong>
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Opioid
         </strong>
         <strong>
          analgesics
         </strong>
         – For patients requiring short-term opioid administration to control pain in the immediate postoperative period, we use a patient-controlled analgesia regimen with
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         [
         <a href="#rid17">
          17
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/134254.html" rel="external">
          "Use of opioids for postoperative pain control", section on 'Patient controlled analgesia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Agents to avoid
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">
          Meperidine
         </a>
         – Although commonly used to treat postoperative shivering (see
         <a class="medical medical_review" href="/z/d/html/94588.html" rel="external">
          "Perioperative temperature management", section on 'Shivering'
         </a>
         ), meperidine is avoided in patients with ESKD. The renally excreted active metabolite normeperidine accumulates and may cause respiratory depression as well as adverse neuroexcitatory effects (eg, myoclonic activity and/or seizures) in patients [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Long-acting opioids
         </strong>
         – We generally avoid long-acting opioids due to potential accumulation of metabolites. However, selected longer-acting opioids may be used after some painful surgical procedures (eg,
         <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">
          hydromorphone
         </a>
         0.1 to 0.2 mg IV every five minutes in the postanesthesia care unit [PACU], titrated to pain, consciousness, and respiratory status). (See
         <a class="medical medical_review" href="/z/d/html/134254.html" rel="external">
          "Use of opioids for postoperative pain control", section on 'Treating pain in the postanesthesia care unit (PACU)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Gabapentinoids
         </strong>
         – Although used in some multimodal pain protocols, patients with ESKD are particularly vulnerable to adverse effects of gabapentinoids (eg, sedation, respiratory depression) [
         <a href="#rid64">
          64,66
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/133187.html" rel="external">
          "Nonopioid pharmacotherapy for acute pain in adults", section on 'Gabapentinoids'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Nonsteroidal antiinflammatory drugs (NSAIDs)
         </strong>
         – NSAIDs are avoided in patients who might have residual kidney function (eg, patients on chronic peritoneal dialysis who still have some daily urine output or those who have initiated hemodialysis within the last 6 to 12 months). (See
         <a class="medical medical_review" href="/z/d/html/7230.html" rel="external">
          "NSAIDs: Acute kidney injury"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1036326617">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preanesthetic management
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Elective surgery
         </strong>
         – Prior to elective surgery, patients with end-stage kidney disease (ESKD) on dialysis are assessed for comorbidities that may impact anesthetic and surgical care. Management of chronically administered medications is similar to that for those without ESKD. (See
         <a class="local">
          'Elective surgery: Assessment and medication management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Emergency surgery
         </strong>
         – For emergency surgical procedures, the nephrology service is consulted when urgent preoperative dialysis may be desirable to treat severe hyperkalemia, metabolic acidosis, or intravascular volume overload. Institution of alternative therapies may be necessary if dialysis is not feasible.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Hyperkalemia
         </strong>
         – If potassium is ≥5.5 mEq/L, we dialyze if time allows, since even one to two hours of hemodialysis reduces potassium concentration. If dialysis is not possible and potassium is &gt;6.5 mEq/, intravenous (IV)
         <a class="drug drug_general" data-topicid="9186" href="/z/d/drug information/9186.html" rel="external">
          calcium chloride
         </a>
         , insulin, or bicarbonate may be administered, or intraoperative continuous kidney replacement therapy or hemodialysis may be initiated  (
         <a class="graphic graphic_algorithm graphicRef109740" href="/z/d/graphic/109740.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_table graphicRef74169" href="/z/d/graphic/74169.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Management of hyperkalemia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Intravascular volume overload
         </strong>
         – Risks of moderate or severe preoperative volume overload are weighed against risks of delaying surgery for dialysis. (See
         <a class="local">
          'Management of intravascular volume overload'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Bleeding
         </strong>
         – If uremia-induced platelet dysfunction is suspected, we suggest administration of IV
         <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">
          desmopressin
         </a>
         (dDAVP) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). For patients with active bleeding, platelets are administered even in the absence of thrombocytopenia.
         <strong>
         </strong>
         (See
         <a class="local">
          'Management of bleeding'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vascular access
         </strong>
         – Veins on the back of the hand are used for peripheral venous catheters; the dominant arm is preferred. We avoid any arteriovenous fistula or graft, potential future fistula sites (eg, antecubital veins and cephalic vein at the wrist), and the hemodialysis catheter. Exceptions may occur in an emergency situation when alternative vascular access is challenging, or to avoid multiple attempts to obtain IV access or insertion of a new central venous catheter (CVC). We also avoid intra-arterial cannulation in the extremity with a fistula or graft. (See
         <a class="local">
          'Vascular access'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intraoperative anesthetic management
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Local anesthesia
         </strong>
         – Local anesthesia with monitored anesthesia care (MAC) is often selected if appropriate for the surgical procedure, thereby avoiding general anesthesia with multiple anesthetic agents that may have delayed metabolism and excretion. Short-acting IV sedative, anxiolytic, or analgesic agents may be administered in reduced carefully titrated doses  (
         <a class="graphic graphic_table graphicRef110394" href="/z/d/graphic/110394.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Local anesthesia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Regional anesthesia
         </strong>
         – A regional anesthetic technique (eg, peripheral nerve block, neuraxial anesthesia) is often selected if appropriate for the surgical procedure, thereby avoiding general anesthesia, as well as providing superior postoperative analgesia. (See
         <a class="local">
          'Regional anesthesia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          General anesthesia
         </strong>
         (See
         <a class="local">
          'General anesthesia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Induction
         </strong>
         – General anesthesia is typically induced with a reduced carefully titrated dose of
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         (eg, 1 to 2 mg/kg).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         If rapid sequence induction and intubation (RSII) is necessary,
         <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">
          succinylcholine
         </a>
         (SCh) can be used as the neuromuscular blocking agent (NMBA) if potassium is &lt;5.5 mEq/L. However, we avoid SCh if potassium is ≥5.5 mEq/L, and use the nondepolarizing NMBA
         <a class="drug drug_general" data-topicid="9872" href="/z/d/drug information/9872.html" rel="external">
          rocuronium
         </a>
         instead, with planned
         <a class="drug drug_general" data-topicid="105866" href="/z/d/drug information/105866.html" rel="external">
          sugammadex
         </a>
         reversal.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         If RSII is unnecessary, an NMBA with slower onset (eg,
         <a class="drug drug_general" data-topicid="9270" href="/z/d/drug information/9270.html" rel="external">
          cisatracurium
         </a>
         ,
         <a class="drug drug_general" data-topicid="9872" href="/z/d/drug information/9872.html" rel="external">
          rocuronium
         </a>
         ) can be used. Alternative techniques without use of any NMBA include a
         <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">
          remifentanil
         </a>
         intubation technique, or use of
         <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">
          sevoflurane
         </a>
         3.5% for three minutes plus a reduced dose of
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         (ie, 0.5 to 1 mg/kg). (See
         <a class="local">
          'Induction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Maintenance
         </strong>
         – Inhalation-based or total IV anesthesia (TIVA), or combinations of IV and inhalation agents may be used to maintain anesthesia. A short-acting opioid may be carefully titrated.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Fluid management
         </strong>
         – We typically select a balanced electrolyte solution unless the patient is hyperkalemic. In such cases, we select normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         . In rare circumstances when urgent and significant volume expansion is necessary, 5% albumin may be administered. Transfusion is avoided when possible, but red blood cells (RBCs) are administered if hemoglobin is &lt;7 g/dL, particularly with ongoing surgical bleeding. (See
         <a class="local">
          'Fluid management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Glucose control
         </strong>
         – We maintain blood glucose at &lt;180 mg/dL (&lt;10 mmol/L). (See
         <a class="local">
          'Glucose control'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Postoperative analgesia
         </strong>
         – We use a multimodal approach to postoperative analgesia including nonpharmacologic techniques (eg, neuraxial analgesia, peripheral nerve blocks, wound infiltration with local anesthesia), nonopioid analgesics (eg,
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         ,
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         ), and opioid analgesics (typically, patient-controlled analgesia with
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         ). We avoid gabapentinoids,
         <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">
          meperidine
         </a>
         , long-acting opioids, and nonsteroidal anti-inflammatory agents. (See
         <a class="local">
          'Postoperative analgesia'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Strid H, Simrén M, Stotzer PO, et al. Delay in gastric emptying in patients with chronic renal failure. Scand J Gastroenterol 2004; 39:516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salles Junior LD, Santos PR, dos Santos AA, de Souza MH. Dyspepsia and gastric emptying in end-stage renal disease patients on hemodialysis. BMC Nephrol 2013; 14:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calvo R, Suárez E, Rodríguez-Sasiain JM, Martínez I. The influence of renal failure on the kinetics of intravenous midazolam: an "in vitro" and "in vivo" study. Res Commun Chem Pathol Pharmacol 1992; 78:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vinik HR, Reves JG, Greenblatt DJ, et al. The pharmacokinetics of midazolam in chronic renal failure patients. Anesthesiology 1983; 59:390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Driessen JJ, Vree TB, Guelen PJ. The effects of acute changes in renal function on the pharmacokinetics of midazolam during long-term infusion in ICU patients. Acta Anaesthesiol Belg 1991; 42:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spina SP, Ensom MH. Clinical pharmacokinetic monitoring of midazolam in critically ill patients. Pharmacotherapy 2007; 27:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aslam S, Friedman EA, Ifudu O. Electrocardiography is unreliable in detecting potentially lethal hyperkalaemia in haemodialysis patients. Nephrol Dial Transplant 2002; 17:1639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khattak HK, Khalid S, Manzoor K, Stein PK. Recurrent life-threatening hyperkalemia without typical electrocardiographic changes. J Electrocardiol 2014; 47:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cobo Sánchez JL, Alconero Camarero AR, Casaus Pérez M, et al. Hyperkalaemia and haemodialysis patients: eletrocardiographic changes. J Ren Care 2007; 33:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plane AF, Marsan PE, du Cheyron D, Valette X. Rapidly changing ECG in hyperkalaemia after succinylcholine. Lancet 2019; 393:1983.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weisberg LS. The risk of preoperative hyperkalemia. Semin Dial 2003; 16:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cooper JR, Kurtz SB, Sawyer MD, Narr BJ. Intraoperative hemodialysis during emergency laparotomy. Anesthesiology 2000; 93:1356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ilson BE, Bland PS, Jorkasky DK, et al. Intraoperative versus routine hemodialysis in end-stage renal disease patients undergoing open-heart surgery. Nephron 1992; 61:170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Troianos CA, Jobes DR, Ellison N. Ultrasound-guided cannulation of the internal jugular vein. A prospective, randomized study. Anesth Analg 1991; 72:823.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hind D, Calvert N, McWilliams R, et al. Ultrasonic locating devices for central venous cannulation: meta-analysis. BMJ 2003; 327:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Practice Guidelines for Central Venous Access 2020: An Updated Report by the American Society of Anesthesiologists Task Force on Central Venous Access. Anesthesiology 2020; 132:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trainor D, Borthwick E, Ferguson A. Perioperative management of the hemodialysis patient. Semin Dial 2011; 24:314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jorgensen MS, Farres H, James BLW, et al. The Role of Regional versus General Anesthesia on Arteriovenous Fistula and Graft Outcomes: A Single-Institution Experience and Literature Review. Ann Vasc Surg 2020; 62:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aitken E, Jackson A, Kearns R, et al. Effect of regional versus local anaesthesia on outcome after arteriovenous fistula creation: a randomised controlled trial. Lancet 2016; 388:1067.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallieni M, Hollenbeck M, Inston N, et al. Clinical practice guideline on peri- and postoperative care of arteriovenous fistulas and grafts for haemodialysis in adults. Nephrol Dial Transplant 2019; 34:ii1.
          </a>
         </li>
         <li class="breakAll">
          Gogarten W, Van Aken H, Büttner J, et al. Regional anaesthesia and thromboembolism prophylaxis/anticoagulation: Revised recommendations of the German Society of Anaesthesiology and Intensive Care Medicine. Anasthesiol Intensivmed Notfallmed Schmerzther 2007; 48:S109. www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=2&amp;cad=rja&amp;uact=8&amp;ved=0CCUQFjAB&amp;url=http%3A%2F%2Fwww.ak-regionalanaesthesie.dgai.de%2Fempfehlungen-links%2Fempfehlungen%2Fdoc_download%2F63-rueckenmarksnahe-regionalanaesthesien-und-thrombo-embolieprophylaxeantithrombotische-medikatio (Accessed on November 15, 2014).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Working Party:, Association of Anaesthetists of Great Britain &amp; Ireland, Obstetric Anaesthetists' Association, Regional Anaesthesia UK. Regional anaesthesia and patients with abnormalities of coagulation: the Association of Anaesthetists of Great Britain &amp; Ireland The Obstetric Anaesthetists' Association Regional Anaesthesia UK. Anaesthesia 2013; 68:966.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horlocker TT, Vandermeuelen E, Kopp SL, et al. Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition). Reg Anesth Pain Med 2018; 43:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirvelä M, Olkkola KT, Rosenberg PH, et al. Pharmacokinetics of propofol and haemodynamic changes during induction of anaesthesia in uraemic patients. Br J Anaesth 1992; 68:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ickx B, Cockshott ID, Barvais L, et al. Propofol infusion for induction and maintenance of anaesthesia in patients with end-stage renal disease. Br J Anaesth 1998; 81:854.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thapa S, Brull SJ. Succinylcholine-induced hyperkalemia in patients with renal failure: an old question revisited. Anesth Analg 2000; 91:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryan DW. Preoperative serum cholinesterase concentration in chronic renal failure. Clinical experience of suxamethonium in 81 patients undergoing renal transplant. Br J Anaesth 1977; 49:945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fahey MR, Rupp SM, Fisher DM, et al. The pharmacokinetics and pharmacodynamics of atracurium in patients with and without renal failure. Anesthesiology 1984; 61:699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bryson HM, Faulds D. Cisatracurium besilate. A review of its pharmacology and clinical potential in anaesthetic practice. Drugs 1997; 53:848.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sparr HJ, Beaufort TM, Fuchs-Buder T. Newer neuromuscular blocking agents: how do they compare with established agents? Drugs 2001; 61:919.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Conzen PF, Nuscheler M, Melotte A, et al. Renal function and serum fluoride concentrations in patients with stable renal insufficiency after anesthesia with sevoflurane or enflurane. Anesth Analg 1995; 81:569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Conzen PF, Kharasch ED, Czerner SF, et al. Low-flow sevoflurane compared with low-flow isoflurane anesthesia in patients with stable renal insufficiency. Anesthesiology 2002; 97:578.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Higuchi H, Adachi Y, Wada H, et al. The effects of low-flow sevoflurane and isoflurane anesthesia on renal function in patients with stable moderate renal insufficiency. Anesth Analg 2001; 92:650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ebert TJ, Arain SR. Renal responses to low-flow desflurane, sevoflurane, and propofol in patients. Anesthesiology 2000; 93:1401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishiyama T, Aibiki M, Hanaoka K. Inorganic fluoride kinetics and renal tubular function after sevoflurane anesthesia in chronic renal failure patients receiving hemodialysis. Anesth Analg 1996; 83:574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Groudine SB, Fragen RJ, Kharasch ED, et al. Comparison of renal function following anesthesia with low-flow sevoflurane and isoflurane. J Clin Anesth 1999; 11:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mazze RI, Callan CM, Galvez ST, et al. The effects of sevoflurane on serum creatinine and blood urea nitrogen concentrations: a retrospective, twenty-two-center, comparative evaluation of renal function in adult surgical patients. Anesth Analg 2000; 90:683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ebert TJ, Frink EJ Jr, Kharasch ED. Absence of biochemical evidence for renal and hepatic dysfunction after 8 hours of 1.25 minimum alveolar concentration sevoflurane anesthesia in volunteers. Anesthesiology 1998; 88:601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ebert TJ, Messana LD, Uhrich TD, Staacke TS. Absence of renal and hepatic toxicity after four hours of 1.25 minimum alveolar anesthetic concentration sevoflurane anesthesia in volunteers. Anesth Analg 1998; 86:662.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kharasch ED, Frink EJ Jr, Zager R, et al. Assessment of low-flow sevoflurane and isoflurane effects on renal function using sensitive markers of tubular toxicity. Anesthesiology 1997; 86:1238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bito H, Ikeda K. Closed-circuit anesthesia with sevoflurane in humans. Effects on renal and hepatic function and concentrations of breakdown products with soda lime in the circuit. Anesthesiology 1994; 80:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldberg ME, Cantillo J, Larijani GE, et al. Sevoflurane versus isoflurane for maintenance of anesthesia: are serum inorganic fluoride ion concentrations of concern? Anesth Analg 1996; 82:1268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morio M, Fujii K, Satoh N, et al. Reaction of sevoflurane and its degradation products with soda lime. Toxicity of the byproducts. Anesthesiology 1992; 77:1155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonsowski CT, Laster MJ, Eger EI 2nd, et al. Toxicity of compound A in rats. Effect of increasing duration of administration. Anesthesiology 1994; 80:566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonsowski CT, Laster MJ, Eger EI 2nd, et al. Toxicity of compound A in rats. Effect of a 3-hour administration. Anesthesiology 1994; 80:556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoke JF, Shlugman D, Dershwitz M, et al. Pharmacokinetics and pharmacodynamics of remifentanil in persons with renal failure compared with healthy volunteers. Anesthesiology 1997; 87:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hill LR, Pichel AC. Respiratory arrest after cadaveric renal transplant. Eur J Anaesthesiol 2009; 26:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiggum DC, Cork RC, Weldon ST, et al. Postoperative respiratory depression and elevated sufentanil levels in a patient with chronic renal failure. Anesthesiology 1985; 63:708.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage 2004; 28:497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michelsen LG, Hug CC Jr. The pharmacokinetics of remifentanil. J Clin Anesth 1996; 8:679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phillips BJ, Hunter JM. Use of mivacurium chloride by constant infusion in the anephric patient. Br J Anaesth 1992; 68:492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maddineni VR, Mirakhur RK, McCoy EP. Recovery of mivacurium block with or without anticholinesterases following administration by continuous infusion. Anaesthesia 1994; 49:946.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cronnelly R, Stanski DR, Miller RD, et al. Renal function and the pharmacokinetics of neostigmine in anesthetized man. Anesthesiology 1979; 51:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Boer HD, Driessen JJ, Marcus MA, et al. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study. Anesthesiology 2007; 107:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Staals LM, Snoeck MM, Driessen JJ, et al. Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study. Br J Anaesth 2010; 104:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Staals LM, Snoeck MM, Driessen JJ, et al. Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function. Br J Anaesth 2008; 101:492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cammu G, Van Vlem B, van den Heuvel M, et al. Dialysability of sugammadex and its complex with rocuronium in intensive care patients with severe renal impairment. Br J Anaesth 2012; 109:382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yunos NM, Bellomo R, Hegarty C, et al. Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA 2012; 308:1566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Potura E, Lindner G, Biesenbach P, et al. An acetate-buffered balanced crystalloid versus 0.9% saline in patients with end-stage renal disease undergoing cadaveric renal transplantation: a prospective randomized controlled trial. Anesth Analg 2015; 120:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacobi J, Bircher N, Krinsley J, et al. Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients. Crit Care Med 2012; 40:3251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feringa HH, Vidakovic R, Karagiannis SE, et al. Impaired glucose regulation, elevated glycated haemoglobin and cardiac ischaemic events in vascular surgery patients. Diabet Med 2008; 25:314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noordzij PG, Boersma E, Schreiner F, et al. Increased preoperative glucose levels are associated with perioperative mortality in patients undergoing noncardiac, nonvascular surgery. Eur J Endocrinol 2007; 156:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           NICE-SUGAR Study Investigators, Finfer S, Chittock DR, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360:1283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ohnuma T, Horres CR 3rd, Raghunathan K, et al. Trends in multimodal analgesics among end-stage renal disease patients undergoing lower extremity amputation in the US from 2009 to 2018. Br J Anaesth 2022; 128:e43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szeto HH, Inturrisi CE, Houde R, et al. Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure of cancer. Ann Intern Med 1977; 86:738.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ishida JH, McCulloch CE, Steinman MA, et al. Gabapentin and Pregabalin Use and Association with Adverse Outcomes among Hemodialysis Patients. J Am Soc Nephrol 2018; 29:1970.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 94254 Version 24.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15223673" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Delay in gastric emptying in patients with chronic renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24330675" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Dyspepsia and gastric emptying in end-stage renal disease patients on hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1475530" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The influence of renal failure on the kinetics of intravenous midazolam: an "in vitro" and "in vivo" study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6638545" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The pharmacokinetics of midazolam in chronic renal failure patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1767626" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The effects of acute changes in renal function on the pharmacokinetics of midazolam during long-term infusion in ICU patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17316150" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Clinical pharmacokinetic monitoring of midazolam in critically ill patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12198216" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Electrocardiography is unreliable in detecting potentially lethal hyperkalaemia in haemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23973093" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Recurrent life-threatening hyperkalemia without typical electrocardiographic changes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19160884" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Hyperkalaemia and haemodialysis patients: eletrocardiographic changes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31084970" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Rapidly changing ECG in hyperkalaemia after succinylcholine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12535308" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The risk of preoperative hyperkalemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11046229" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Intraoperative hemodialysis during emergency laparotomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1630541" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Intraoperative versus routine hemodialysis in end-stage renal disease patients undergoing open-heart surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2035868" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Ultrasound-guided cannulation of the internal jugular vein. A prospective, randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12919984" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Ultrasonic locating devices for central venous cannulation: meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31821240" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Practice Guidelines for Central Venous Access 2020: An Updated Report by the American Society of Anesthesiologists Task Force on Central Venous Access.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21435000" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Perioperative management of the hemodialysis patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31382001" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The Role of Regional versus General Anesthesia on Arteriovenous Fistula and Graft Outcomes: A Single-Institution Experience and Literature Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27492881" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Effect of regional versus local anaesthesia on outcome after arteriovenous fistula creation: a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31192372" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Clinical practice guideline on peri- and postoperative care of arteriovenous fistulas and grafts for haemodialysis in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31192372" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Clinical practice guideline on peri- and postoperative care of arteriovenous fistulas and grafts for haemodialysis in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23905877" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Regional anaesthesia and patients with abnormalities of coagulation: the Association of Anaesthetists of Great Britain&amp;Ireland The Obstetric Anaesthetists' Association Regional Anaesthesia UK.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29561531" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1540461" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Pharmacokinetics of propofol and haemodynamic changes during induction of anaesthesia in uraemic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10211008" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Propofol infusion for induction and maintenance of anaesthesia in patients with end-stage renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10866919" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Succinylcholine-induced hyperkalemia in patients with renal failure: an old question revisited.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/911595" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Preoperative serum cholinesterase concentration in chronic renal failure. Clinical experience of suxamethonium in 81 patients undergoing renal transplant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6239574" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The pharmacokinetics and pharmacodynamics of atracurium in patients with and without renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9129870" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Cisatracurium besilate. A review of its pharmacology and clinical potential in anaesthetic practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11434449" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Newer neuromuscular blocking agents: how do they compare with established agents?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7653825" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Renal function and serum fluoride concentrations in patients with stable renal insufficiency after anesthesia with sevoflurane or enflurane.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12218523" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Low-flow sevoflurane compared with low-flow isoflurane anesthesia in patients with stable renal insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11226095" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The effects of low-flow sevoflurane and isoflurane anesthesia on renal function in patients with stable moderate renal insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11149433" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Renal responses to low-flow desflurane, sevoflurane, and propofol in patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8780284" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Inorganic fluoride kinetics and renal tubular function after sevoflurane anesthesia in chronic renal failure patients receiving hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10434215" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Comparison of renal function following anesthesia with low-flow sevoflurane and isoflurane.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10702457" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : The effects of sevoflurane on serum creatinine and blood urea nitrogen concentrations: a retrospective, twenty-two-center, comparative evaluation of renal function in adult surgical patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9523801" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Absence of biochemical evidence for renal and hepatic dysfunction after 8 hours of 1.25 minimum alveolar concentration sevoflurane anesthesia in volunteers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9495434" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Absence of renal and hepatic toxicity after four hours of 1.25 minimum alveolar anesthetic concentration sevoflurane anesthesia in volunteers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9197292" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Assessment of low-flow sevoflurane and isoflurane effects on renal function using sensitive markers of tubular toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8291733" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Closed-circuit anesthesia with sevoflurane in humans. Effects on renal and hepatic function and concentrations of breakdown products with soda lime in the circuit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8638803" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Sevoflurane versus isoflurane for maintenance of anesthesia: are serum inorganic fluoride ion concentrations of concern?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1466466" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Reaction of sevoflurane and its degradation products with soda lime. Toxicity of the byproducts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7908177" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Toxicity of compound A in rats. Effect of increasing duration of administration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8141452" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Toxicity of compound A in rats. Effect of a 3-hour administration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9316957" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Pharmacokinetics and pharmacodynamics of remifentanil in persons with renal failure compared with healthy volunteers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19521299" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Respiratory arrest after cadaveric renal transplant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2932984" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Postoperative respiratory depression and elevated sufentanil levels in a patient with chronic renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15504625" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Opioids in renal failure and dialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8982900" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The pharmacokinetics of remifentanil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1642938" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Use of mivacurium chloride by constant infusion in the anephric patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7802237" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Recovery of mivacurium block with or without anticholinesterases following administration by continuous infusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/382915" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Renal function and the pharmacokinetics of neostigmine in anesthetized man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17667567" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20007792" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18653492" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22732111" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Dialysability of sugammadex and its complex with rocuronium in intensive care patients with severe renal impairment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23073953" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25185593" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : An acetate-buffered balanced crystalloid versus 0.9% saline in patients with end-stage renal disease undergoing cadaveric renal transplantation: a prospective randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23164767" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18201208" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Impaired glucose regulation, elevated glycated haemoglobin and cardiac ischaemic events in vascular surgery patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17218737" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Increased preoperative glucose levels are associated with perioperative mortality in patients undergoing noncardiac, nonvascular surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19318384" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Intensive versus conventional glucose control in critically ill patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34852927" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Trends in multimodal analgesics among end-stage renal disease patients undergoing lower extremity amputation in the US from 2009 to 2018.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/869353" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure of cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29871945" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Gabapentin and Pregabalin Use and Association with Adverse Outcomes among Hemodialysis Patients.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
